Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. (scientific article published on February 2017)

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

Q54685505

Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer

Q57907638

Epithelial ovarian tumors of borderline malignancy

Q68583288

Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy

Q78618340

Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma

Q79825860

Grading ovarian serous carcinoma using a two-tier system

Q79934949

Low-grade serous primary peritoneal carcinoma

Q83597688

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

Q83636947

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

Q30724410

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

Q34729698

Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update

Q34743455

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer

Q35461505

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

Q35510378

Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.

Q35947034

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer

Q36346641

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes

Q36545843

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.

Q36750622

The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer

Q36751103

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

Q36768921

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

Q36898398

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

Q37652173

Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary

Q38167276

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.

Q38312260

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

Q39638363

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

Q39859169

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

Q40301883

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.

Q40488633

High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.

Q51753726

P433

issue

P407